Comparative Bioavailability of a Microsize and Ultramicrosize Griseofulvin Formulation in Man

12Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The bioavailability of 500 mg of a microsize formulation of griseofulvin has been compared to two new ultramicrosize griseofulvin formulations, two 165 mg tablets and a 330 mg tablet, in sixteen healthy, male, volunteers in a randomized crossover study design. Based on the griseofulvin plasma levels measured at specified times over a 48-hour period, the major bioavailability parameters (i.e., area under plasma concentration-time curve, maximum plasma concentration, and time to reach maximum plasma concentration) were determined and statistically evaluated. The results showed that one 330 mg ultramicrosize tablet is bioequivalent to two 165 mg ultramicrosize griseofulvin tablets and that either ultramicrosize griseofulvin dosage regimen is bioequivalent to 500 mg of the microsize griseofulvin formulation. © 1982, SAGE Publications. All rights reserved.

Cite

CITATION STYLE

APA

Lin, C., Lim, J., Digiore, C., Gural, R., & Symchowicz, B. (1982). Comparative Bioavailability of a Microsize and Ultramicrosize Griseofulvin Formulation in Man. Journal of International Medical Research, 10(4), 274–277. https://doi.org/10.1177/030006058201000415

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free